On November 18, 2024, Elite Pharmaceuticals, Inc. (Elite) announced in a press release that it had secured approval from the US Food and Drug Administration (FDA) for a generic version of Vyvanse® ...

Vyvanse (lisdexamfetamine) is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat attention deficit hyperactivity disorder (ADHD) in adults and some children.

After prescribing, keep prescription records, educate patients about abuse, monitor for signs of abuse and overdose, and re-evaluate the need for Vyvanse use. <6yrs: not established. Do not ...

Elite received approval from the Food and Drug Administration for a generic version of Vyvanse (lisdexamfetamine dimesylate) capsules in strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg ...

IQVIA reported annual sales for the twelve months ending September 2024 of $4.3 billion for the brand and generic market for this product. About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals ( (ELTP) ) has provided an update.

for a generic version of Vyvanse® (Lisdexamfetamine Dimesylate) with strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg capsules. The product is indicated for the treatment of ...